SCHEMBL5596376

SCHEMBL5596376

CC(C)(C)OC(=O)N1CCCC(N2CCc3cncc4c(Br)ccc2c34)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.44
UCHL1 P09936 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
HPGDS O60760 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
BRD4 O60885 1/20 0.36
HCAR1 Q9BXC0 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
SCN9A Q15858 1/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
USP30 Q70CQ3 4/20 0.35
CYP2C9 P11712 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
BTK Q06187 1/20 0.35
KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5596990 0.95 USP30 (0.40) FPR2SCN9APIK3R1PIK3CAUSP30
SCHEMBL5596372 0.89 FPR2 (0.41) FPR2
SCHEMBL5597012 0.84 FPR2 (0.44) FPR2UCHL1PRMT5WDR77HPGDS
SCHEMBL5596980 0.84 USP30 (0.42) FPR2UCHL1PRMT5WDR77HPGDS
SCHEMBL5597144 0.82 FPR2 (0.44) FPR2UCHL1PRMT5WDR77HPGDS
SCHEMBL5596618 0.82 BRD4 (0.42) FPR2UCHL1PRMT5WDR77HPGDS
SCHEMBL5596994 0.80 VNN1 (0.33)
SCHEMBL5597044 0.80 SCN9A (0.42) FPR2UCHL1HPGDSBRD4HCAR1
SCHEMBL5596748 0.80 HTR6 (0.41) FPR2PRMT5WDR77HPGDSBRD4
SCHEMBL5596364 0.79 TNF (0.40) FPR2PRMT5WDR77HPGDSBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1829876-A1 NITROGENEOUS TRICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2007-09-05 EP disclosed
US-20060247266-A1 Nitrogen-containing tricyclic compounds ASAHI KASEI PHARMA CORPORATION (JP) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247266-A1 Nitrogen-containing tricyclic compounds MYO1B, CHRM1, MYL12A FPR2 3865/4885UCHL1 2859/4885PRMT5 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.